1739-P: Impact of IGlarLixi on Glycemic Variability (GV): A Participant-Level Exploratory Pooled Analysis of the Global LixiLan Clinical Trial Program

Introduction and Objective: iGlarLixi is a once-daily, fixed-ratio combination of the basal insulin glargine 100 U/mL (Gla-100) and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), lixisenatide (Lixi). The aim was to evaluate the impact of iGlarLixi on glycemic variability (GV) by assessing postprandial glucose (PPG) excursions and derived time in tight range (dTITR) in people with type 2 diabetes (PwT2D) from the global LixiLan clinical trial program. Methods: This participant-level exploratory analysis pooled data from the LixiLan-L, LixiLan-O and LixiLan-G trials; the time to end of treatment was 30, 30 and 26 weeks, respectively. Comparators for the studies were: Gla-100 (LixiLan-L), Gla-100 and Lixi (LixiLan-O) and daily- or weekly-GLP-1 RA therapy (LixiLan-G). Endpoints for this analysis were change in PPG excursions and dTITR. Results: In 2,403 participants, iGlarLixi significantly improved PPG excursions at 0.5 hours and 1 hour after a meal versus Gla-100 (p<0.0001 for both; Table). iGlarLixi also robustly reduced PPG excursions after 2 hours versus Gla-100 (p<0.0001) and GLP-1 RA (p=0.0004). Further, iGlarLixi significantly improved dTITR versus all comparators (p<0.0001 for all; Table). Conclusion: iGlarLixi demonstrated consistent improvements in PPG excursions and GV versus Gla-100 and GLP-1 RA therapies in PwT2D. Disclosure L. Czupryniak: Speaker's Bureau; Current; Abbott. Advisory Panel; Current; Abbott. Research Support; Current; Abbott. O. Deyneli: Speaker's Bureau; Ended; Abbott Diabetes. Advisory Panel; Ended; Sanofi. Speaker's Bureau; Ended; Sanofi. Advisory Panel; Ended; Roche Diabetes Care. Speaker's Bureau; Ended; Roche Diabetes Care, Novo Nordisk, Boehringer Ingelheim International GmbH, AstraZeneca, Eli Lilly and Company. Advisory Panel; Ended; Eli Lilly and Company. Speaker's Bureau; Ended; Recordati S.p.A, Servier Laboratories, Bilim Ilac. Advisory Panel; Ended; World Medicine, Humanis Saglik, SABA Ilac, Celtis Ilaç. Speaker's Bureau; Ended; Sanovel. S.H. Assaad-Khalil: Advisory Panel; Current; Sanofi. B. Saboo: None. M.E. Al-Sofiani: Speaker's Bureau; Ended; Medtronic, Dexcom, Inc. Research Support; Current; Dexcom, Inc. Research Support; Ended; Medtronic. Speaker's Bureau; Ended; Insulet Corporation, Abbott Diabetes, Sanofi. F. Lauand: Employee; Current; Sanofi. A. Alvarez: Employee; Current; Sanofi. L. Melas-Melt: None. J. Rosenstock: Advisory Panel; Ended; Amgen Inc. Research Support; Current; Amgen Inc., AstraZeneca. Advisory Panel; Ended; Biomea Fusion, Corcept Therapeutics, Eli Lilly and Company. Research Support; Ended; Eli Lilly and Company. Advisory Panel; Ended; Gan & Lee Pharmaceuticals, Hanmi Pharm. Co., Ltd., Boehringer Ingelheim International GmbH. Research Support; Ended; Boehringer Ingelheim International GmbH. Advisory Panel; Ended; Novo Nordisk. Research Support; Ended; Novo Nordisk, Pfizer Inc. Advisory Panel; Ended; Regeneron Pharmaceuticals Inc. Research Support; Ended; Regeneron Pharmaceuticals Inc. Advisory Panel; Ended; Regor. Research Support; Ended; Regor. Advisory Panel; Ended; Roche Pharmaceuticals. Advisory Panel; Current; Sanofi. Research Support; Current; Sanofi. Advisory Panel; Ended; Structure Therapeutics, Terns. Funding Funded by Sanofi